Altria Group's Q4 Earnings Impacted by Declining Cigarette Sales

Business by 2FIRSTS.ai
Feb.01.2024
Altria Group's Q4 Earnings Impacted by Declining Cigarette Sales
Altria Group's Q4 net income is predicted to reach $5.1 billion, with a 2% decrease from last year.

According to a report by Barron's on January 31, tobacco industry giant Altria Group is set to release its fourth-quarter financial earnings. Analysts predict that Altria Group's net income will reach $5.1 billion, which is similar to the figure for 2022. Net income for the year is expected to decline by 2% compared to the same period last year, amounting to $2.1 million, with earnings per share at $1.18.

 

Despite more optimistic expectations for fourth-quarter performance compared to the third quarter, cigarette prices have increased by 8.7% and sales volume has dropped by 11.6% compared to the same period last year. The tobacco department's net income has declined by 5.3% compared to last year, highlighting the sales pressure. Many consumers are switching to alternative products such as heated tobacco, e-cigarettes, and oral nicotine pouches.

 

The weak sales performance highlights the pressure faced by tobacco companies, as British American Tobacco and Altria Group announced a $32 billion cut in cigarette brands in December last year, triggering a major industry sell-off. Altria Group's sales volume for oral tobacco products declined by 3.3% compared to the previous year, but the higher prices offset this loss, resulting in a 2.3% increase in net income for the sector.

 

The Chief Financial Officer of the company, Saul Mancozo, has stated that inflation, declining consumer income, and the emergence of illicit e-cigarettes have had an impact on the customer base. Despite a low stock price, Altria Group has managed to boost shareholder returns through share repurchases and dividend payments. In the first nine months of 2023, the company repurchased 16.3 million shares, returning $732 million in cash to shareholders, and is expected to complete an additional $268 million worth of stock repurchases by the end of 2023.

 

Further Exploration and Development

 

Altria Group is a company known for its reliable dividend returns, having experienced 54 consecutive years of dividend growth. The management has stated their plans for a single-digit annual growth, and has made an optimistic projection for the full-year earnings per share in 2023, expecting it to grow between $4.91 and $4.98, representing a 1.5% to 3% increase.

 

Despite the limited performance of Altria Group's stock due to rising commodity prices, Wall Street analysts remain optimistic towards the stock. The average target price is $47, representing an almost 18% increase from the current $40. Goldman Sachs analysts predict that Altria Group will offset declining sales volumes with strong price increases in the fourth quarter, but they also point out that the stock may continue to trade within a range until the trend of declining sales stabilizes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
A University of Louisville research team published a study in an American Heart Association journal suggesting that synthetic cooling agents used in e-cigarettes, including WS-3 and WS-23, may disrupt cardiac electrical activity and increase arrhythmia risk. In animal experiments, WS-23 tripled premature heartbeats.
Jun.16
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
British American Tobacco (BAT) subsidiary Vuse Alto has recently adjusted its price tiers in U.S. convenience store channels, leveraging low-cost device kits and pod promotions to reinforce its positioning in the mid-priced closed-system e-cigarette market.
Jun.17
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
According to Chinese patent records, a “nicotine tooth patch” application filed by China Tobacco Hubei Industrial Corporation (CTHB) and Hubei Xinye Tobacco Sheet Development Co., Ltd. was published on May 19, 2026. The filing proposes a nicotine gel patch that adheres to the tooth surface, especially the lingual side, to reduce displacement, foreign-body sensation, and accidental swallowing risks associated with existing oral nicotine products.
Jun.10
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Researchers at the Chinese Academy of Sciences reconstructed nicotine biosynthesis in non-tobacco plants and yeast systems, highlighting how advances in synthetic biology could gradually reshape future nicotine production technologies and challenge regulatory frameworks built around tobacco-derived definitions.
Special Report
May.07
Maine Approves Vape Stewardship Bill Requiring Producers to Manage End-of-Life Devices
Maine Approves Vape Stewardship Bill Requiring Producers to Manage End-of-Life Devices
The Maine Legislature has passed LD 1519, a bill that would establish a producer-funded stewardship program for electronic smoking devices, requiring manufacturers and importers to manage the collection, transportation, recycling and disposal of end-of-life products, particularly disposable vapes containing lithium-ion batteries.
Jun.12
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18